C-MYC和MXI1在晚期肺腺癌组织中的表达及其临床意义

C-MYC and MXI1 Protein Expressions in the Advanced Lung Adenocarcinoma

目的观察C-MYC和MXI1在晚期肺腺癌组织中的表达,同时探讨两者的相关性及其临床意义。方法使用免疫组化S-P法检测C-MYC和MXI1在100例晚期肺腺癌组织中表达情况,并分析其与晚期肺腺癌临床病理特征的关系。结果 C-MYC和MXI1在晚期肺腺癌组织中的阳性表达率分别为60.00%和55.00%。晚期肺腺癌组织中C-MYC、MXI1的表达呈负相关(r=-0.206,P<0.05)。C-MYC阴性患者比C-MYC阳性患者具有较长的生存时间(21.00个月vs 15.00个月),差异有统计学意义(χ~2=10.890,P<0.001);而MXI1阳性患者比MXI1阴性患者具有较长的生存时间(21.00个月vs 13.00个月),差异有统计学意义(χ~2=15.080,P<0.001)。结论 C-MYC和MXI1的异常表达可能与晚期肺腺癌的预后密切相关。

Objective To investigate the expressions of C-MYC and MXI1 protein and the clinical significance in the advanced lung adenocarcinoma. Methods The expressions of C-MYC and MXI1 in the advanced lung adeno-carcinoma were detected by immunohistochemistry, and the relationship between two proteins and clinicopathologic feature was analyzed. Results The positive expression rates of C-MYC and MXI1 in the advanced lung adenocarcinoma were 60.00% and 55.00% respectively. C-MYC was negatively related with MXI1 in the advanced lung adenocarcinoma（ r = - 0. 206 ,P 〈 0.05 ）. The overall survival of the patients with negative C-MYC were longer than the patients with positive C-MYC （21.00 vs 15. 00 months ; X2 = 10. 890, P 〈 0. 001 ）. The overall survival of the patients with positive MXI1 were longer than the patients with negative MXI1 （21.00 vs 13.00 months; X2 = 15. 080, P 〈 0.001 ）. Conclusion Abnormal expressions of C-MYC and MXI1 may be related to prognosis of advanced lung adenocarcinoma.